biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > RNAi

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon May 03, 2023 12:23pm

153 Views

Post# 35427773

RE:RE:RE:RNAi

"..if only XB3 could be shown to work in monkeys."

Maybe Chiesi has monkey data. Very important week ahead for Chiesi in LSDs. Maybe J&J is testing it on monkeys. J&J has been over one year since the multi-product collaboration was signed. It was said expanded at the AGM. Rathjen recently 'liked' this post on Linkedin:

Wayne Drevets, M.D.

Vice President, Disease Area Team Leader, Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson

2w Edited

Mental health conditions, like depression, can cause feelings of loneliness, isolation and hopelessness. In this video, artist Greyson shares his journey coping with depressive symptoms and how his rediscovered passion for art and community brought healing to his life.